Skip to main navigation
Skip to main content
Denali Therapeutics
  • Home
  • Scientific Approach
    • GENETIC PATHWAY POTENTIAL
    • ENGINEERING BRAIN DELIVERY
    • BIOMARKER-DRIVEN DEVELOPMENT
    • PUBLICATIONS
  • Pipeline
  • Patients
  • Investor & Media Relations
    • Press Releases
    • Events
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
  • Leadership
  • Partnering
  • Careers
    • Job Openings
    • STEM Outreach Overview
    • Student Internships
    • Postdoc Program
  • Contact

SEC Filings

Sign Up For Updates
Filing date Form Description View
Mar 19, 2024 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-24-000092.pdf
0001714899-24-000092.rtf
0001714899-24-000092.xls
Mar 01, 2024 D Notice of Exempt Offering of Securities View HTML
0001714899-24-000088.pdf
0001714899-24-000088.rtf
0001714899-24-000088.xls
Feb 28, 2024 S-8 Securities offered to employees pursuant to employee benefit plans View HTML
0001714899-24-000087.pdf
0001714899-24-000087.rtf
0001714899-24-000087.xls
Feb 28, 2024 10-K Annual report which provides a comprehensive overview of the company for the past year View HTML
0001714899-24-000086.pdf
0001714899-24-000086.rtf
0001714899-24-000086.xls
Feb 27, 2024 8-K Report of unscheduled material events or corporate event View HTML
0001714899-24-000075.pdf
0001714899-24-000075.rtf
0001714899-24-000075.xls
Feb 27, 2024 8-K Report of unscheduled material events or corporate event View HTML
0001714899-24-000076.pdf
0001714899-24-000076.rtf
0001714899-24-000076.xls
Feb 20, 2024 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-24-000066.pdf
0001714899-24-000066.rtf
0001714899-24-000066.xls
Feb 16, 2024 8-K Report of unscheduled material events or corporate event View HTML
0001714899-24-000065.pdf
0001714899-24-000065.rtf
0001714899-24-000065.xls
Feb 15, 2024 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-24-000060.pdf
0001714899-24-000060.rtf
0001714899-24-000060.xls
Feb 15, 2024 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-24-000062.pdf
0001714899-24-000062.rtf
0001714899-24-000062.xls
Pagination
  • First page «
  • Previous page ‹
  • …
  • Page 12
  • Page 13
  • Current page 14
  • Page 15
  • Page 16
  • …
  • Next page ›
  • Last page »
Displaying 131 - 140 of 720 results

Sign up for email alerts

Stay in the loop with updates on the latest Denali news delivered right to your inbox


  • Investor & Media Relations

CONTACT US

161 Oyster Point Blvd- South San Francisco, CA 94080

© 2025 Denali Therapeutics

  • Privacy Policy
  • Terms of Use

©2025 Denali Therapeutics | 161 Oyster Point Boulevard, South San Francisco, CA 94080

  • Privacy Policy
  • Terms of Use